Nxera Pharma disclosed on 14 October that it had signed an exclusive agreement with Synmosa for an insomnia drug in 8 APAC countries. Its share price recently rose from a closing price of ¥1,183 on 14 October to ¥1,248 on 16 October. In its earnings results, first-half revenue for the fiscal year ending December 2026 was ¥18.9 billion, while interim profit turned positive.
On the same day, Nxera Pharma announced an exclusive agreement with Synmosa for an insomnia drug in 8 APAC countries as part of its sleep-related drug partnership business. The share price moved modestly on the day and the following day, with a reaction to the announcement of the news.
In its earnings results, first-half revenue for the fiscal year ending December 2026 rose 25.3% year on year to ¥18.9 billion, while interim profit turned positive from a loss in the same period of the previous year. The company said that increased revenue from Quviviq, higher milestone income and cost reductions contributed to the result.
Future earnings checkpoints include expanding sales of core products and accumulating milestone income from partnerships, while it has also been noted that earnings may fluctuate depending on development decisions by partners and progress toward approval. The next earnings announcement is scheduled for 30 October.